ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
Avexis, Inc. (delisted)

Avexis, Inc. (delisted) (AVXS)

217.83
0.00
( 0.00% )
更新日時: 09:00:00

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

通貨
217.83
買値
9.50
売値
217.96
出来高
-
0.00 日の範囲 0.00
0.00 52 週間の範囲 0.00
前日終値
217.83
始値
-
時刻
最終取引時間
-
平均取引量 (3 か月)
-
財務取引量
-
VWAP
-

AVXS 最新ニュース

AveXis Reports First Quarter 2018 Financial and Operating Results

-- Significant progress across operating functions including licensing, clinical trials and regulatory interactions -- -- AVXS-101 pre-BLA meeting with FDA is scheduled to be held in June 2018...

AveXis Provides Update on Proposed Acquisition by Novartis AG

CHICAGO, May 01, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...

AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3

CHICAGO, April 25, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...

AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-10...

– A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial – – All patients in the therapeutic dose cohort in the Phase 1 trial...

AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology

CHICAGO, April 19, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...

WEISSLAW LLP Investigates AveXis Inc. Acquisition

WEISSLAW LLP Investigates AveXis Inc. Acquisition PR Newswire NEW YORK, April 11, 2018 NEW YORK, April 11, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty...

AveXis Enters Agreement to be Acquired by Novartis AG for $8.7 billion

Novartis to acquire AveXis for $218 per share in cash AveXis’ lead product candidate, AVXS-101, expected to enhance Novartis’s position as a gene therapy and neuroscience leader Transaction...

AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1

CHICAGO, March 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...

AveXis Enters into Licensing Agreement with Genethon

CHICAGO and ÉVRY, France , March 13, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) and Genethon today announced they have entered into an exclusive, worldwide license agreement...

AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results

– On track to request pre-BLA meeting with FDA in Q2 2018 –– Intends to initiate pivotal trial in SMA Type 1 in Europe and multi-national pre-symptomatic SMA study in the first half of 2018 –...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
SPPLSIMPPLE Ltd
US$ 0.98
(206.25%)
316.45M
NUWENewellis Inc
US$ 2.8199
(107.35%)
90.73M
STAFStaffing 360 Solutions Inc
US$ 2.77
(62.94%)
48.91M
OMICSingular Genomics Systems Inc
US$ 21.2535
(57.90%)
282.61k
ADNAdvent Technologies Holdings Inc
US$ 3.00
(57.89%)
60.71M
SSPEW Scripps Company
US$ 2.2093
(-37.24%)
2.89M
GCTKGlucoTrack Inc
US$ 1.16
(-33.33%)
69.44k
INVZWInnoviz Technologies Ltd
US$ 0.0642
(-33.13%)
996
ILLRTriller Group Inc
US$ 2.9398
(-31.31%)
1.94M
ELABElevai Labs Inc
US$ 0.0201
(-30.45%)
218.14M
SPPLSIMPPLE Ltd
US$ 0.98
(206.25%)
316.45M
ELABElevai Labs Inc
US$ 0.0201
(-30.45%)
219.06M
SQQQProShares UltraPro Short QQQ
US$ 7.4401
(0.00%)
133.58M
NVDANVIDIA Corporation
US$ 138.1949
(2.06%)
131.7M
PLUGPlug Power Inc
US$ 2.465
(17.94%)
92.43M